Exscientiaがアジアの創薬マーケットを狙った子会社を日本に設立

Exscientia社(エクセンシア)は、人工知能(AI)創薬で世界最先端を行く企業ですが、この度日本に子会社Exscientia株式会社を設立し、アジアにおけるビジネスを強化します。Exscientia株式会社は本社を大阪市に置き、田中大輔博士が責任者となります。

Exscientia continues expansion with establishment of a subsidiary in Japan to target the pharmaceutical market across Asia

Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company announces the establishment of a subsidiary, Exscientia K.K to spearhead  its pharmaceutical interests across Asia.

Exscientia K.K. is headquartered in Osaka, Japan, and led by Dr Daisuke Tanaka, an experienced medicinal chemist who previously was Director of the Innovative Chemistry Group at Sumitomo Dainippon Pharma (DSP).

Celgene and Exscientia enter 3-year AI drug discovery collaboration focused on accelerating drug discovery in oncology and autoimmunity

Oxford, UK, 21 March 2019: Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered a three-year AI drug discovery partnership with leading biopharma company Celgene, including an initial $25 million upfront payment and eligibility to receive substantial milestones based on the clinical, regulatory and commercial success of the program. In addition, Exscientia is due to receive tiered royalties on net sales on any product resulting from the collaboration. Exscientia will apply its full-stack AI drug discovery capabilities to the execution of the entire project – from gene to the drug candidate.

Exscientia hires Director of Data Engineering to scale up its AI drug discovery platform

Following a highly successful year and several drug discovery milestones using its flagship AI platform, Exscientia are pleased to welcome Andrew Douglas as the new Director of Data Engineering.

Andrew joins Exscientia from Winton Capital, a global investment management and data science company, where he led the design and creation of platforms, algorithms and models to automate data processing, analyse data and predict outcomes as a core element of the firm’s strategic investment approach.

Andrew has 10+ years’ experience in data engineering and in developing systems that support the functioning of AI-powered approaches. At Exscientia, he will leverage his expertise to streamline, scale up the company’s data systems and automated processes alongside supporting the AI to perform design work. This will enable Exscientia’s drug discovery teams to increase productivity and therefore the quality of drug candidates generated through the Centaur Chemist™ platform.

“We’re thrilled to welcome Andrew to the team”, says Adrian Schreyer, CTO at Exscientia. “This is a very exciting time for us, as we are rapidly expanding our talent in computer science and drug discovery in anticipation of rapid growth, so this timing could not have been better.”

Since Exscientia’s inception in 2012, the company has grown exponentially securing 6 major pharma collaborations (Evotec, Roche, GSK, Sanofi, Sumitomo, and Sunovion) and rapidly growing its proprietary pipeline of drugs. Earlier this year, it has secured a $26 million Series B investment. The company is led by an industry-recognised executive team with years of experience at leading firms like Pfizer, GSK and Goldman Sachs, and several industry awards amongst them. It is now on a path to ramp up its technology capabilities.

Andrew commented, “What drew me to Exscientia’s mission is that its use of technology is strongly driven by objective results and their impact on drug discovery productivity. There is also a clear recognition at Exscientia of the synergy possible between human expertise and machine intelligence and a motivation to really make a difference to patients’ lives. I very much look forward to applying my experience in data volume, variety, velocity and veracity acquired through my time in the financial sector into drug discovery and working with a world-class team to deliver these goals.”

Exscientia Raises US$26 Million in Series B Financing Round to Accelerate Scaling as the Leading AI Drug Discovery Company

NEW INVESTORS CELGENE CORPORATION AND GT HEALTHCARE CAPITAL PARTNERS JOIN SERIES A INVESTOR EVOTEC.

Exscientia – the world-leading Artificial Intelligence (AI)-driven drug discovery company – today announces it has raised US$26 million in a Series B financing round. This will be used to scale the company’s pipeline and advance selected programmes towards clinical development. The round included participation from new investors Celgene Corporation and specialist healthcare investor GT Healthcare Capital Partners, as well as existing investor Evotec AG.

Exscientia Initiates Sixth AI Drug Discovery Partnership

EXSCIENTIA TO RECEIVE UP TO CHF 67 MILLION IN UPFRONT PAYMENTS, RESEARCH SUPPORT AND MILESTONE PAYMENTS IN DISCOVERY COLLABORATION WITH ROCHE

Exscientia – the world-leading Artificial Intelligence (AI)-driven drug discovery company - is pleased to announce a drug discovery collaboration with Roche. 

Exscientia will apply its cutting-edge, Centaur Chemist™, AI drug discovery platform to design pre-clinical drug candidates for Roche. Roche has the exclusive rights to develop and market the drug candidates resulting from the collaboration.

Exscientia receives upfront and research funding as well as pre-clinical, development and commercial milestone payments. Together, the combined financial reward is worth up to CHF 67 million to Exscientia, plus tiered royalties on the annual net sales of any products resulting from the collaboration.

Exscientia Builds “Full Stack” AI-driven Drug Discovery Capabilities through Acquisition of Kinetic Discovery

Exscientia Builds “Full Stack” AI-driven Drug Discovery Capabilities through Acquisition of Kinetic Discovery

Exscientia, the company leading the use of Artificial Intelligence (AI) in drug discovery, announces that is has acquired the biophysics specialists, Kinetic Discovery, a private UK company. The acquisition builds up Exscientia’s capabilities for the tackling novel drug targets to create first-in-class drug candidates by seeding its algorithms with data generated through the use of fragment screening and structural biology. The addition of Kinetic’s complementary expertise enables Exscientia to create a “full stack” AI-driven drug discovery company to go rapidly from gene to clinical candidate for any druggable target of choice. The acquisition of Kinetic is part of Exscientia’s growth strategy to develop a proprietary drug pipeline and to enhance its support of existing and future partnerships.

Leading AI-driven drug discovery company Exscientia expands to The Oxford Science Park

Leading AI-driven drug discovery company Exscientia expands to The Oxford Science Park

Facilities in The Schrödinger Building to bring together AI experts and biologists

Oxford, UK, 1 November 2018 - In a key point in its growth strategy, Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is expanding its Oxford presence to the new Schrödinger Building on The Oxford Science Park, one of the UK's leading parks for science and technology companies. In its new facilities, Exscientia is bringing together its computer scientists, drug designers and biologists under one roof to allow it to rapidly expand its platform development and proprietary drug discovery portfolio. The move also allows the firm to expand its recruitment activities in Oxford. Exscientia is the third occupant of The Oxford Science Park’s new Schrödinger Building, and it expects to move in by the end of the year.